About
We are on a mission to bring treatment to millions at risk of cancer with no options.
Astrivax Therapeutics (Astrivax) is a clinical-stage biopharmaceutical company on a mission to end virus-driven cancer, the second leading preventable cause of cancer after smoking. Its clinically validated Launch-iT platform generates durable, antigen-specific T-cell responses that clear virus-infected cells, supported by a scalable, tech-transfer–ready manufacturing process.
Astrivax’s lead program targets human papillomavirus 16 (HPV16), a leading cause of virus-driven cancers, including cervical cancer and head and neck cancer. The company is advancing its platform toward clinical proof-of-concept for persistent HPV infections and plans to expand across additional HPV-driven cancers. Beyond oncology, Astrivax is exploring applications in autoimmune diseases where viral infections are increasingly recognized as drivers of disease.
Our core values
Authentic
We are genuine, We embrace honesty, accountability, transparency and openness. We work towards a common goal.
Entrepeneural
We innovate with passion for science. We are curious and take ownership to explore solutions. We are courageous and dare ‘to do’.
Disciplined
We plan and execute on our goals with determination. We strive to excellence and challenge ourselves and our work. We value timely, informed decision-making.
Caring
We care for each other and believe in the power of collaboration. We create fun in our workplace and care for the patients by relentlessly searching transformative cures.